Is Certolizumab Pegol Safe and Effective in the Treatment of Patients with Moderate to Severe Crohn’s Disease? A Meta-analysis of Controlled Clinical Trials

CITEDBY Reports

  1. Shilan Mozaffari, Shekoufeh Nikfar, Amir Hossein Abdolghaffari, Mohammad Abdollahi, . New biologic therapeutics for ulcerative colitis and Crohn's disease. Expert Opinion on Biological Therapy, 2014; 14(5): 583.
    Crossref
  2. Gloria SZ Tun, Alan J Lobo, . Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn’s disease. Expert Opinion on Drug Metabolism & Toxicology, 2015; 11(2): 317.
    Crossref
  3. Alice Capogrosso Sansone, Stefania Mantarro, Marco Tuccori, Elisa Ruggiero, Sabrina Montagnani, Irma Convertino, Alessandra Marino, Matteo Fornai, Luca Antonioli, Tiberio Corona, Danila Garibaldi, Corrado Blandizzi, . Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis. Drug Safety, 2015; 38(10): 869.
    Crossref